Alan P. Lyss, MD

Results from a phase 1 trial showed that a personalized mRNA neoantigen vaccine can stimulate an immune response in patients with pancreatic ductal adenocarcinoma.

Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.